GDRX Stock Analysis: Goodrx Holdings | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 1.245m USD | 12M Return: 16% | US38246G1085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.94M
EPS Trend: 55.2%
Qual. Beats: 0
Rev. Trend: 76.5%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.1 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
GoodRx Holdings, Inc. (NASDAQ: GDRX) operates a digital platform that helps U.S. consumers compare prescription drug prices and access discounted rates at pharmacies. Founded in 2011 and headquartered in Santa Monica, California, the company has expanded beyond its core prescription pricing service into subscription programs, pharmaceutical manufacturer solutions, telehealth through the GoodRx Care platform, and pet healthcare products. It works with pharmacy benefit managers (PBMs), the intermediaries that manage drug formularies and negotiate pricing between payers, pharmacies, and manufacturers.
Listed on NASDAQ since its September 2020 IPO, GoodRx is classified within the Health Care Technology sub-industry of the broader Health Care sector. The companys business model centers on price transparency in prescription drugs, a segment that has grown alongside rising U.S. medication costs and increased consumer demand for digital healthcare tools.
- PBM regulatory scrutiny threatens prescription discount business model
- Pharma manufacturer solutions revenue accelerates high-margin growth
- Competition from SingleCare and RxSaver pressures prescription market share
| Net Income: 16.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -3.89 > 1.0 |
| NWC/Revenue: 56.22% < 20% (prev 52.47%; Δ 3.75% < -1%) |
| CFO/TA 0.09 > 3% & CFO 201.6m > Net Income 16.2m |
| Net Debt (295.2m) to EBITDA (170.8m): 1.73 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (348.1m) vs 12m ago -2.55% < -2% |
| Gross Margin: 88.05% > 18% (prev 91.21%; Δ -3.16% > 0.5%) |
| Asset Turnover: 42.89% > 50% (prev 60.66%; Δ -17.77% > 0%) |
| Interest Coverage Ratio: 2.01 > 6 (EBIT TTM 82.2m / Interest Expense TTM 40.8m) |
| A: 0.19 (Total Current Assets 1.60b - Total Current Liabilities 1.16b) / Total Assets 2.34b |
| B: -0.60 (Retained Earnings -1.40b / Total Assets 2.34b) |
| C: 0.04 (EBIT TTM 82.2m / Avg Total Assets 1.83b) |
| D: 0.38 (Book Value of Equity 647.6m / Total Liabilities 1.70b) |
| Altman-Z'' = -0.01 = B |
| DSRI: 3.0 (Receivables 1.26b/202.3m, Revenue 785.2m/799.9m) |
| GMI: 1.04 (GM 91.21% / 88.05%) |
| AQI: 0.55 (AQ_t 0.30 / AQ_t-1 0.55) |
| SGI: 0.98 (Revenue 785.2m / 799.9m) |
| TATA: -0.08 (NI 16.2m - CFO 201.6m) / TA 2.34b) |
| Beneish M = -1.64 (Cap -4..+1) = CCC |
As of November 16, 2026, the stock is trading at USD 3.56 with a total of 788,255 shares traded. Over the past week, the price has changed by +1.42%, over one month by +3.19%, over three months by -4.30% and over the past year by +15.96%.
Current recommended Stop Loss: 3.20 (which is 10.1% or 2.2 ATR below the current price).
Goodrx Holdings has received a consensus analysts rating of 3.36. Therefore, it is recommended to hold GDRX.
- StrongBuy: 3
- Buy: 1
- Hold: 8
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 4 | 11% |
P/E Trailing = 73.0
P/E Forward = 10.2881
P/S = 1.5858
P/B = 1.8701
Revenue TTM = 785.2m USD
EBIT TTM = 82.2m USD
EBITDA TTM = 170.8m USD
Long Term Debt = 481.6m USD (from longTermDebt, last quarter)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 591.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 52.4m
Net Debt = 295.2m USD (calculated: Debt 591.3m - CCE 296.1m)
Enterprise Value = 1.54b USD (1.25b + Debt 591.3m - CCE 296.1m)
Interest Coverage Ratio = 2.01 (Ebit TTM 82.2m / Interest Expense TTM 40.8m)
EV/FCF = 10.57x (Enterprise Value 1.54b / FCF TTM 145.7m)
FCF Yield = 9.46% (FCF TTM 145.7m / Enterprise Value 1.54b)
FCF Margin = 18.56% (FCF TTM 145.7m / Revenue TTM 785.2m)
Net Margin = 2.07% (Net Income TTM 16.2m / Revenue TTM 785.2m)
Gross Margin = 88.05% ((Revenue TTM 785.2m - Cost of Revenue TTM 93.8m) / Revenue TTM)
Gross Margin QoQ = 89.52% (prev 78.38%)
Tobins Q-Ratio = 0.66 (Enterprise Value 1.54b / Total Assets 2.34b)
Interest Expense / Debt = 6.90% (Interest Expense 40.8m / Debt 591.3m)
Taxrate = 44.81% (6.93m / 15.5m)
NOPAT = 45.4m (EBIT 82.2m * (1 - 44.81%))
Current Ratio = 1.38 (Total Current Assets 1.60b / Total Current Liabilities 1.16b)
Debt / Equity = 0.91 (Debt 591.3m / totalStockholderEquity, last quarter 647.6m)
Debt / EBITDA = 1.73 (Net Debt 295.2m / EBITDA 170.8m)
Debt / FCF = 2.03 (Net Debt 295.2m / FCF TTM 145.7m)
Total Stockholder Equity = 621.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.89% (Net Income 16.2m / Total Assets 2.34b)
RoE = 2.61% (Net Income TTM 16.2m / Total Stockholder Equity 621.6m)
RoCE = 7.45% (EBIT 82.2m / Capital Employed (Equity 621.6m + L.T.Debt 481.6m))
RoIC = 3.92% (NOPAT 45.4m / Invested Capital 1.16b)
WACC = 7.86% (E(1.25b)/V(1.84b) * Re(9.78%) + D(591.3m)/V(1.84b) * Rd(6.90%) * (1-Tc(0.45)))
Discount Rate = 9.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.49 | Cagr: -4.94%
[DCF] Terminal Value 76.58% ; FCFF base≈140.8m ; Y1≈152.2m ; Y5≈187.0m
[DCF] Fair Price = 23.98 (EV 2.86b - Net Debt 295.2m = Equity 2.57b / Shares 107.2m; r=8.35% [WACC [floored]]; 5y FCF grow 9.29% → 2.50% )
EPS Correlation: 55.18 | EPS CAGR: 6.15% | SUE: 0.0 | # QB: 0
Revenue Correlation: 76.55 | Revenue CAGR: 2.30% | SUE: 2.09 | # QB: 3
EPS current Quarter (2026-09-30): EPS=0.08 | Chg30d=+0.00% | Revisions=-10% | Analysts=11
EPS current Year (2026-12-31): EPS=0.30 | Chg30d=+0.00% | Revisions=-8% | GrowthEPS=-13.4% | GrowthRev=+0.2%
EPS next Year (2027-12-31): EPS=0.35 | Chg30d=-0.79% | Revisions=-25% | GrowthEPS=+16.2% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: -15% (up=7, down=10)